4//SEC Filing
Sobel Alan D. 4
Accession 0001104659-25-005354
CIK 0001175151other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 8:32 PM ET
Size
14.8 KB
Accession
0001104659-25-005354
Insider Transaction Report
Form 4
Sobel Alan D.
Director
Transactions
- Exercise of In-Money
Common Stock
2025-01-17$1.00/sh+21,950$21,950→ 123,807 total - Exercise of In-Money
Subscription Rights (right to buy)
2025-01-17−21,950→ 0 totalExercise: $1.00From: 2024-12-09Exp: 2025-01-10→ Common Stock (21,950 underlying) - Other
Series A Right Warrants
2025-01-17+21,950→ 21,950 totalFrom: 2025-01-17Exp: 2025-02-24→ Common Stock (21,950 underlying) - Other
Series B Right Warrants
2025-01-17+21,950→ 21,950 totalFrom: 2025-01-17Exp: 2025-04-10→ Common Stock (21,950 underlying)
Holdings
- 2,000(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date").
- [F2]Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person.
- [F3]These shares are held in the Bernard Sobel Revocable Trust (the "Trust"), for which the reporting person is a trustee and a named beneficiary. Accordingly, the reporting person may be deemed the beneficial owner of the shares held in the Trust.
- [F4]The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
- [F5]The Series A Right Warrants expire 45 calendar days following the Closing Date.
- [F6]The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.
- [F7]The Series B Right Warrants expire 90 calendar days following the Closing Date.
Documents
Issuer
Cytosorbents Corp
CIK 0001175151
Entity typeother
Related Parties
1- filerCIK 0001639386
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 8:32 PM ET
- Size
- 14.8 KB